Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.

J Gerontol A Biol Sci Med Sci 2017 Oct;72(11):1586-1593

Berman Center for Outcomes and Clinical Research, Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minnesota.

Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.

Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).

Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.

Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.

Download full-text PDF

Source
http://dx.doi.org/10.1093/gerona/glw342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861878PMC
October 2017
87 Reads

Publication Analysis

Top Keywords

reducing events
8
low-dose aspirin
8
placebo-controlled trial
8
aspirin reducing
8
events elderly
8
physical disability
8
aspirin
7
lower percentages
4
aspirin baseline
4
baseline data
4
data include
4
indication aspirin
4
december 2014
4
percentages diabetes
4
disability contraindication
4
include physical
4
contraindication indication
4
countries lower
4
ended december
4
lifestyle personal
4

References

(Supplied by CrossRef)

National Center for Health Statistics et al.
The Modified Mini-Mental State (3MS) examination
Teng et al.
J Clin Psychiatry 1987

Similar Publications